

IL1b
TNFa
IFNg
MIP1b
Resiquimod
S5a
S73a
S74a
S8a
S63a
S63
S11a
S14a
[Cytokine] pg / mL
[Compound] (μM)
0
0.01
0.1
1
10
100
2000
4000
6000
8000
10000
12000
15000

FIGURE 1



IL1b
TNFa
IFNa
MCP3
[Cytokine] pg / mL
[Compound] (µM)
Resiquimod
S8a
S75a
S18a
S76a
S77a
S78a
S14a
S5a

FIGURE 2



IL1b
TNFa
IFNa
MIP1b
Resiquimod
S5a
S5b
S11a
S11b
S8a
S8b
[Cytokine] pg / mL
[Compound] (μM)
0
0.01
0.1
1
10
5000
10000
15000
20000
200
400
600
30000

FIGURE 3



TNFa
[Cytokine] pg / mL
1500
1000
500
200
150
100
50
0
Untreated
Resiquimod
S8a
S5a
S11a
S8b
S11b
MIP1b
[Cytokine] pg / mL
3000
2000
1000
0
Untreated
Resiquimod
S8a
S5a
S11a
S8b
S11b

FIGURE 4



S18a
S18b
IL1b
[Cytokine] pg / mL
0
100
1000
[Compound] (nM)
S18a
S18b
IL12p40
[Cytokine] pg / mL
0
1000
2000
3000
4000
5000
100
1000
[Compound] (nM free drug)

FIGURE 5



TNFa
[Cytokine] pg / mL
0
1000
2000
3000
Untreated
non-targeted
targeted cmpd 1
targeted cmpd 4
targeted cmpd 2
targeted cmpd 7
targeted cmpd 5
targeted cmpd 3
targeted cmpd 6
MIP1b
[Cytokine] pg / mL
0
1000
2000
3000
Untreated
non-targeted
targeted cmpd 1
targeted cmpd 4
targeted cmpd 2
targeted cmpd 7
targeted cmpd 5
targeted cmpd 3
targeted cmpd 6

FIGURE 6



IL1b
[Cytokine] pg / mL
0
100
200
300
400
500
600
700
1
100
1000
10000
[Compound] (ng/ml)
targeted cmpd 9
targeted cmpd 10
non-targeted cmpd 9
non-targeted cmpd 10
IL12p40
[Cytokine] pg / mL
0
200
400
600
800
1000
1200
1400
1
100
1000
10000
[Compound] (ng/ml)
targeted cmpd 9
targeted cmpd 10
non-targeted cmpd 9
non-targeted cmpd 10

FIGURE 7



targeted cmpd 4
targeted cmpd 3
targeted cmpd 10
targeted cmpd 9
targeted cmpd 7
targeted cmpd 8
TNFa
[Cytokine] pg / mL
10000
8000
6000
4000
2000
0
1
[Compound] (µM or µg/ml)
IL6
[Cytokine] pg / mL
15000
10000
5000
0
1
[Compound] (µM or µg/ml)

FIGURE 8



Mouse Plasma
targeted mAB
targeted cmpd 10
targeted cmpd 9
MWH%
Time (hours)
0
5
10
15
0
20
40
60
80
100
Human Plasma
targeted mAB
targeted cmpd 9
targeted cmpd 10
MWH%
Time (hours)
0
5
10
15
0
20
40
60
80
100

FIGURE 9



Tumor Volume (mm³)
1200
1000
800
600
400
200
0
10
15
20
Days Post Tumor Implant
Untreated
targeted cmpd 3, 2 mg/kg
non-targeted cmpd 3, 2 mg/kg
targeted cmpd 4, 2 mg/kg
non targeted cmpd 4, 2 mg/kg
CT26
Percent survival
100
50
0
10
20
30
40
Days Post Tumor Implant
non-targeted cmpd 3, 2 mg/kg
targeted cmpd 3, 2mg/kg
non-targeted cmpd 4, 2 mg/kg
targeted cmpd 4, 2 mg/kg
Untreated

FIGURE 10



Tumor Volume (mm³)
1000
800
600
400
200
0
10
15
20
Days Post Tumor Implant
Untreated
targeted cmpd 7 2 mg/kg
non-targeted cmpd 7 2 mg/kg
targeted cmpd 8 2 mg/kg
non-targeted cmpd 8 2 mg/kg
targeted cmpd 4 2 mg/kg
CT26
Percent survival
100
80
60
40
20
0
10
15
20
25
30
35
Days Post Tumor Implant
targeted cmpd 4 2 mg/kg
non-targeted cmpd 8 2 mg/kg
targeted cmpd 7 2 mg/kg
non-targeted cmpd 7 2 mg/kg
targeted cmpd 7 2 mg/kg
Untreated

FIGURE 11



Median tumor volume (mm3)
1200
1000
800
600
400
200
0
10
15
20
Days Post Tumor Implant
Untreated
targeted cmpd 4 2 mg/kg
non-targeted cmpd 4 2 mg/kg
targeted cmpd 3 2 mg/kg
non-targeted cmpd 3 2 mg/kg
targeted cmpd 10 2 mg/kg
non-targeted cmpd 10
targeted cmpd 9 2 mg/kg
non-targeted cmpd 9 2 mg/kg
MC38
Percent survival
100
80
60
40
20
0
10
20
30
40
50
Days Post Tumor Implant
Untreated
targeted cmpd 4 2 mg/kg
non-targeted cmpd 4 2 mg/kg
targeted cmpd 3 2 mg/kg
non-targeted cmpd 3 2 mg/kg
targeted cmpd 10 2 mg/kg
non-targeted cmpd 10 2 mg/kg
targeted cmpd 9 2 mg/kg
non-targeted cmpd 9 2 mg/kg

FIGURE 12



2000
1500
1000
500
0
Tumor Volume (mm^3)
10
15
20
Days Post Tumor Implant
Untreated
targeted cmpd 9 2.4 mg/kg
non targeted cmpd 9 2.4 mg/kg
CT26
100
80
60
40
20
0
Percent survival
0
20
40
60
Days Post Tumor Implant
Untreated
targeted cmpd 9 2.4 mg/kg
non-targeted cmpd 9 2.4 mg/kg

FIGURE 13



Tumor Volume (mm3)
1000
800
600
400
200
0
10
15
20
25
Days Post Tumor Implant
Untreated
cmpd S18a 0.05 mg/kg
targeted cmpd 10 2 mg/kg
non-targeted cmpd 10 2 mg/kg
targeted cmpd 9 2 mg/kg
non-targeted cmpd 9 2 mg/kg
Renca
Percent survival
100
80
60
40
20
0
20
40
60
Days post tumor implant
Untreated
cmpd S18a 0.05 mg/kg
targeted cmpd 10 2 mg/kg
non-targeted cmpd 10 2 mg/kg
targeted cmpd 9 2 mg/kg
non-targeted cmpd 9 2 mg/kg

FIGURE 14



MIP1b
15000
10000
5000
0
[Cytokine] pg/mL
0
5
10
15
20
Hrs post dose
cmpd S18b 0.5 mg/kg
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
TNFa
600
400
200
0
[Cytokine] pg/mL
0
5
10
15
20
Hrs post dose
cmpd S18b 0.5 mg/kg
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg

FIGURE 15



MIP1b
8000
6000
4000
2000
0
[Cytokine] pg/ml
0
10
20
Time post dose (Hr)
cmpd S18a 0.05 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg
TNFa
150
100
50
0
[Cytokine] pg/ml
0
10
20
Time post dose (Hr)
cmpd S18a 0.05 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg

FIGURE 16



MIP1b
[Cytokine] pg/ml
10000
8000
6000
4000
2000
0
0 2 4 6 8 10 12 14 16 18 20 22 24
Time post dose (Hr)
Untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg
TNFa
[Cytokine] pg/ml
500
400
300
200
100
0
0 2 4 6 8 10 12 14 16 18 20 22 24
Time post dose (Hr)
Untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg

FIGURE 17



Tumor volume (mm³)
3000
2000
1000
0
10
15
20
25
Days Post Tumor Implant
Vehicle
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg
CT26
Percent survival
100
80
60
40
20
0
10
15
20
25
30
35
Days Post Tumor Implant
Vehicle
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg

FIGURE 18



MIP1b
[Cytokine] pg/ml
3000
2000
1000
0
0
4
8
12
16
20
24
Time post dose (h)
untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg
TNFa
[Cytokine] pg/ml
200
150
100
50
0
0
4
8
12
16
20
24
Time post dose (h)
untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg

FIGURE 19



Tumor volume (mm3)
1000
800
600
400
200
0
0
5
10
15
20
Days Post Tumor Implant
untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-targeted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg
Renca
Percent survival
100
50
0
0
5
10
15
20
25
30
35
Time
Untreated
targeted cmpd 9 2 mg/kg
targeted cmpd 11 2 mg/kg
non-tageted cmpd 9 2 mg/kg
non-targeted cmpd 11 2 mg/kg

FIGURE 20



MIP1b
[Cytokine] MFI
25000
20000
15000
10000
5000
0
0.001
0.01
0.1
1
10
[IDC] (µg/ml)
targeted cmpd 9
targeted cmpd 11
non-targeted cmpd 9
non-targeted cmpd 11
TNFa
[Cytokine] MFI
5000
4000
3000
2000
1000
0
0.01
0.1
1
10
[IDC] (µg/ml)
targeted cmpd 9
targeted cmpd 11
non-targeted cmpd 9
non-targeted cmpd 11

FIGURE 21



Untreated
Isotype compound 11 2 mg/kg
Isotype compound 11 4 mg/kg
Isotype compound 11 8 mg/kg
Isotype compound 9 2 mg/kg
Tumor Volume (mm2)
1000
800
600
400
200
0
0
5
10
15
20
Days Post Tumor Implant
Renca
Percent survival
100
50
0
10
20
30
Days Post Tumor Implant
Untreated
IDC targeted compound 11 2 mg/kg
IDC targeted compound 11 4 mg/kg
IDC targeted compound 11 8 mg/kg
IDC targeted compound 9 2 mg/kg
Tumor Volume (mm2)
1000
800
600
400
200
0
0
5
10
15
20
Days Post Tumor Implant
Renca
Percent survival
100
50
0
10
20
30
Days Post Tumor Implant

FIGURE 22



MIP1b
[Cytokine] pg/ml
10000
8000
6000
4000
2000
0
TNFa
[Cytokine] pg/ml
1200
1000
800
600
400
200
0
2 mg/kg
2 mg/kg
4 mg/kg
8 mg/kg
2 mg/kg
2 mg/kg
4 mg/kg
8 mg/kg
cmpd 9
cmpd 11
cmpd 9
cmpd 11
Targeted
Non-targeted

FIGURE 23



Hek hTLR8
Fold change SEAP over veh
[Compound] (μM)
Hek hTLR7
Fold change SEAP over veh
[Compound] (μM)
Resiquimod
S5A
S8a
S14a
S18a
S75A
S76a
S77a
S78a

FIGURE 24



MC38
C57BL/6 mice
Tumor Volume (mm³)
Day
MC38
TLR7-/- C57BL/6 mice
Tumor Volume (mm³)
Day
Vehicle
1 mg/kg S18a
2 mg/kg non targeted cmpd 9
2 mg/kg targeted cmpd 9
PBS
1 mg/kg free S18a
2 mg/kg non targeted cmpd 9
2 mg/kg targeted cmpd 9
[IL 6] pg/mL
C57BL/6
C57BL/6 TLR7 -/-

FIGURE 25



Renca
Tumor volume (mm3)
1000
800
600
400
200
0
0
5
10
15
20
25
30
Days Post Tumor Implant
untreated
2 mg/kg targeted cmpd 15
2 mg/kg targeted cmpd 14
2 mg/kg targeted cmpd 11
2 mg/kg targeted cmpd 9
Renca
Tumor volume (mm3)
1000
800
600
400
200
0
0
5
10
15
20
25
30
Days Post Tumor Implant
untreated
2 mg/kg non targeted cmpd 15
2 mg/kg non targeted cmpd 14
2 mg/kg non targeted cmpd 11
2 mg/kg non targeted cmpd 9

FIGURE 26



Renca-25
Mean Tumor volume (mm3)
1000
800
600
400
200
0
4
7
10
14
17
Days Post Tumor Implant
Untreated
cmpd 9
cmpd 15
cmpd 11
cmpd 21
cmpd 22
cmpd 27
cmpd 26
Targeted
2 mg/kg

FIGURE 27



4T1
Day 23
Tumor Volume (mm3)
1000
800
600
400
200
0
Untreated
2 mg/kg Immune and tumor target mAb
2 mg/kg Immune and tumor targeted compound 3
2 mg/kg Isotype compound 3
2 mg/kg Immune targeted compound 3

FIGURE 28



IL1b
TNFa
IL6
MIP1b
S18a
S85a
S83a
none
[Cytokine] pg/mL
[Compound] (ug)
0
0.01
0.1
1
50
100
150
200
250
300

FIGURE 29



S18a
S65b
S81a
S82a
S83a
S84a
TNFa
IP10
IL6
MCP1
[Cytokine] pg/mL
[Compound] (µg/ml)
0
0.001
0.01
0.1
1
10
1000
2000
3000
4000
5000
6000
8000
10000
15000

FIGURE 30



PBS
S18a
Isotype IDC
Immune targeted IDC
Day 36
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
B6
TLR7-/-
C57Bl/6
TLR7-/-
Median Tumor volume (mm3)
3000
2000
1000
0
0
10
20
30
40
50
Day

FIGURE 31



Renca-34
Median Tumor volume (mm3)
Days Post Tumor Implant
Day 20
Tumor volume (mm3)
Untreated
Immune targeted mIgG2a-cmpd 14(2) 2 mg/kg 34 nmol/kg
Immune targeted mIgG2a-cmpd 14(2) 5 mg/kg 68 nmol/kg
Immune targeted mIgG2a-cmpd 14(2) 10 mg/kg 136 nmol/kg
Immune targeted mIgG2a-cmpd 9(4) 2.5 mg/kg 68 nmol/kg
Immune targeted mIgG2a-cmpd 9(4) 5 mg/kg 136 nmol/kg
Immune targeted mIgG2a-cmpd 9(10) 1 mg/kg 68 nmol/kg
Immune targeted mIgG2a-cmpd 9(10) 2 mg/kg 136 nmol/kg

FIGURE 32



Renca
renal cell carcinoma
Tumor Volume (mm3)
1000
800
600
400
200
0
0
10
20
30
40
50
Days Post Tumor Implant
3/6 CR
Untreated
2.4 mg/kg EphA2 mIgG2a-cmpd 9(10)
2.4 mg/kg m00 mIgG2a-cmpd 9(10)

FIGURE 33



Renca
Tumor Volume (mm3)
1000
800
600
400
200
0
0
10
20
30
Days Post Tumor Implant
Untreated 0 mg/kg
Isotype mIgG2a-cmpd 11(10) 2 mg/kg
EphA2 mIgG2a-cmpd 11(10) 2 mg/kg

FIGURE 34



CT26
colon carcinoma
Tumor Volume (mm3)
3000
2000
1000
0
10
20
30
40
50
Days Post Tumor Implant
0/6 CR
5/6 CR
Untreated
2.4 mg/kg EphA2 mIgG2a-cmpd 9(10)
2.4 mg/kg Isotype mIgG2a-cmpd 9(10)

FIGURE 35



CT26
Median Tumor volume (mm3)
1200
1000
800
600
400
200
0
10
20
30
40
Days Post Tumor Implant
1/8 CRs
4/8 CRs
Untreated
Isotype hIgG1-cmpd 11(8) 2 mg/kg
EphA2 mIgG2a-cmpd 11(10) 2 mg/kg

FIGURE 36



4T1-35
Tumor Volume (mm3)
1000
800
600
400
200
0
0
10
20
30
40
50
Days Post Tumor Implant
Untreated
EphA2 mIgG2aK 3 mg/kg
EphA2 mIgG2aK-cmpd 9(10) 3 mg/kg

FIGURE 37



CT26
Median Tumor volume (mm3)
1500
1000
500
0
0
10
20
Days Post Tumor Implant
Untreated
Targeted mAb hIgG1 2 mg/kg
Targeted hIgG1-cmpd 11(8) 2 mg/kg
Isotype-cmpd 11(8) 2 mg/kg

FIGURE 38